Purchase this article with an account.
Ana Silvia Serrano-Ahumada, Luis Aguilar-Lozano, Guillermo De Wit, Valeria Sanchez-Huerta, Everardo Hernandez-Quintela; Safety of Implantable Collamer Lens (ICL): 10 years follow-up. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5286.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate safety of posterior chamber phakic lens (ICL) implantation in patients with high myopia.
This retrospective and observational study included 64 patients (106 eyes) who underwent ICL implantation to correct high myopia (>6.00 D) in a period of > 10 years (2006-2016) at Asociacion Para Evitar la Ceguera en Mexico in Mexico City.Main outcomes evaluated rate of ICL explantation, lens opacity, ocular hypertension and endothelial cell density loss; the cumulative risk of ICL explantation was assessed with Kaplan-Meier analysis.
Our study included a total of 64 patients (106 eyes), 15 men and 49 women, with a mean age of 28.6 years. The rate of lens opacity after surgery was 2.8% (3 cases), phacoemulsification was performed in 1 eye with no further complications. Ocular hypertension was observed in 9.4% (10 cases), in 2 cases filtration surgery was performed and 1 patient underwent ICL explantation; the rest of the cases were treated with topical hypotensive agents. Only 1 case presented with significant endothelial cell density loss which resulted in explantation of ICL. The explantation rate of ICL was 4.71% (5 cases). The maximum follow-up was 125 months after implantantion.
ICL implantation provides an excellent long-term safety (at least 10 years) in patients with high myopia. Complications, although uncommon, should be taken into account and all candidates must be notified before ICL implantation due to the important clinical implications that cataract formation, ocular hypertension and endothelial cell count loss might have in a long term basis.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only